Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings Biosimilars Strategy

Coherus Aims To Pull Out $75m In Costs Amid Conservative 2023 Guidance

Three Launches Eyed Next Year, Alongside Recent Ranibizumab Biosimilar

  • Analysis

Executive Summary

Coherus BioSciences saw its Q3 revenues tumble by 45% as it arrived at the firm’s projected nadir. A swathe of launches and a cost-cutting program are targeted to bring the firm back to profitability in 2024.

You may also be interested in...



Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.

Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023

At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).

Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval

Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings Biosimilars Strategy
Latest Headlines

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023

Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

See All
UsernamePublicRestriction

Register

GB152285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By